Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Gene-by-Sleep Duration Interaction for Glycemic Traits in More Than 480,000 Individuals

Wang H, Nagarajan P, Miller CL, Bentley AR, Noordam R, Westerman KE, Brown MR, Kraja AT, O'Connell JR, Schwander K, Li C, Sanghvi MM, Song[...]

Prediction of All-Cause Mortality, Cardiovascular Mortality, and Angiographic Coronary Disease From LVEF Reserve: Findings From the Multicenter REFINE PET Registry

Hijazi W, Zhou J, Miller RJH, Ramirez G, Lemley M, Shanbhag A, Kwiecinski J, Kavanagh PB, Parekh T, Liang JX, Alexanderson E, Carvajal-Juarez I, Slipczuk[...]

Conversational artificial intelligence for geriatric screening: A mixed-methods feasibility study

Naeim A, Cheng J, Spiegel B, Bakshian A, Tetrault E, Mehra M, Amini D, Krut Z, Shang H, Sedrak MS, Bui A, Johnson T, Wang[...]